<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192033</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0466</org_study_id>
    <nct_id>NCT03192033</nct_id>
  </id_info>
  <brief_title>STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures</brief_title>
  <acronym>STEP</acronym>
  <official_title>STEP: Proglide® Versus Femoseal®: A Randomized Controlled Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the past years, arterial closure systems have tended to replace manual compression to
      ensure hemostasis at femoral artery puncture points. Arterial closure systems reduce
      hemostasis and patient immobilization times, thus enabling early resumption of walking. These
      devices have contributed extensively to the development of outpatient stays for cardiology,
      vascular and neuro-radiology procedures.

      However, main arterial closure devices use different technology to close the arterial
      puncture point. For some, hemostasis is achieved by sealing the arteriotomy between two discs
      (an inner and an outer). For others, they are designed to close puncture sites delivering a
      single monofilament polypropylene suture mediated by needles.

      The investigators hypothesis is based on a different efficacy between both arterial closure
      devices for peripheral arterial disease (PAD) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">April 3, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A duplex scan guided retrograde femoral puncture is performed followed by the use of a closure arterial device to ensure hemostasis. Patients are randomly assigned to be closed by Proglide® (Abbott) versus Femoseal® (Terumo)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success defined as hemostasis at the puncture site without major complications.</measure>
    <time_frame>Hour 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major cardio-vascular events</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major punctured femoral artery events during the perioperative period</measure>
    <time_frame>Hour 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of minor punctured femoral artery events during the perioperative period</measure>
    <time_frame>Hour 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking ability</measure>
    <time_frame>Hour 5</time_frame>
    <description>Time before restart of the ambulation measured in minutes from when the sheath of the introducer of the arterial closure system is removed and the moment when the patient is able to walk 100 meters without the recurrence of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation (EQ-5D)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-Outcome Ratio of patient care with FemoSeal® (St Jude) and Proglide® (Abbott)</measure>
    <time_frame>Month 1</time_frame>
    <description>The measure of effectiveness will be the utility obtained from the EQ-5D quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Arterial closure device used is Proglide® (Abbott)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arterial closure device used is Femoseal® (Terumo)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arterial closure to ensure hemostasis at femoral artery puncture points</intervention_name>
    <description>Arterial closure devices used: Proglide® (Abbott)</description>
    <arm_group_label>Arterial closure device used is Proglide® (Abbott)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Proglide® (Abbott)</intervention_name>
    <description>Arterial closure device used: Proglide® (Abbott)</description>
    <arm_group_label>Arterial closure device used is Proglide® (Abbott)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Femoseal® (Terumo)</intervention_name>
    <description>Arterial closure device used: Femoseal® (Terumo)</description>
    <arm_group_label>Arterial closure device used is Femoseal® (Terumo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arterial closure to ensure hemostasis at femoral artery puncture points</intervention_name>
    <description>Arterial closure device used: Femoseal® (Terumo)</description>
    <arm_group_label>Arterial closure device used is Femoseal® (Terumo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years,

          -  Patient with peripheral arterial disease

          -  Endovascular examination or treatment compatible with a 5F to 7F sheath

          -  Walking ability

          -  Patient affiliated with a social security scheme

          -  Patient's signed informed consent form

        Exclusion Criteria:

          -  Under-age patient

          -  Patient of age, but under legal guardianship or care

          -  Contraindication to endovascular treatment

          -  Use of a 8F or greater sheath

          -  Morbidity contraindicating same-day walking

          -  History of ipsilateral open common femoral artery surgery

          -  Stent at the puncture site

          -  Radial or brachial puncture

          -  Antegrade femoral puncture

          -  Acute ischemia

          -  Life expectancy of less than one month

          -  Patient refusal to take part in the study

          -  Participation in another therapeutic trial

          -  Pregnant woman

          -  Allergy to clopidogrel or aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CHAILLOU, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe CHAILLOU, Doctor</last_name>
    <phone>+33 2 40 16 50 93</phone>
    <email>philippe.chaillou@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yann GOUEFFIC, Professor</last_name>
    <phone>+33 2 40 16 50 93</phone>
    <email>yann.goueffic@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Picquet, Doctor</last_name>
      <email>jean.picquet@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Picquet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Gouny, Doctor</last_name>
      <email>pierre.gouny@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Gouny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD La Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Marret, Doctor</last_name>
      <email>olivier.marret@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Marret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice SCHNEIDER, Doctor</last_name>
      <email>Fabrice.SCHNEIDER@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice SCHNEIDER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien Kaladji, Doctor</last_name>
      <email>adrien.kaladji@chur-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Adrien Kaladji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

